Examining What Is Next For Arch Therapeutics [Seeking Alpha]
Arch Therapeutics, Inc. (ARTH)
NASDAQ:AMEX Investor Relations:
ir.archtherapeutics.com
Company Research
Source: Seeking Alpha
Examining What Is Next For Arch Therapeutics Summary Arch now has their first FDA approval. The company expects the review process for the CE Mark to be completed this fall. The stock is about the same price as it was four years ago. On June 26, 2015, I published an article on SeekingAlpha introducing Arch Therapeutics: “ The Cheapest Medical Device Stock I've Ever Seen Arch had a strong patent position and a very important advantage: Their product, AC5, is regulated as a device, not a drug. That offered a faster, lower-cost path to approval. So what's happened since mid-2015? Lots. For less than $37 million, Arch was able to take AC5 from an idea to FDA approval on December 17, 2018. But the company had to pivot to approval for external use in wound care for problems like pressure ulcers (bedsores), diabetic foot ulcers, and burns. Around the end of this year, they will file an IND (Investigational New Device) application with the FDA for approval of a clinical trial for internal use
Show less
Read more
Impact Snapshot
Event Time:
ARTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTH alerts
High impacting Arch Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTH
Sec Filings
- 11/13/24 - Form SC
- 11/7/24 - Form 8-K
- 11/4/24 - Form 8-K
- ARTH's page on the SEC website